Latest Conference Articles

Investigators believe this connection could be used to prognosticate and prevent future cases of diabetic retinopathy.

The combination therapy of aflibercept and micropulsed yellow laser treatment results in good anatomical responses and substantially fewer intravitreal injections.

The mitochondria-targeting medication preserves photoreceptor health regardless of baseline photoreceptor outer segment thinning burden.

Interim data from the ongoing TEASE-3 trial have indicated preservation of best-corrected visual acuity.

Compared to sham treatment, the PER-001 implant is safe, efficacious, and effective in reducing macular ischemia, vascular leakage, and microaneurysms.

Based on an open-label extension of the OAKS and DERBY trials, pegcetacoplan has highlighted the superior effectiveness of early versus delayed GA treatment.

Results from the DAVIO 2 trial have shown the equivalence of a single dose of EYP-1901 to aflibercept Q8W in visual acuity over 6 months.

In a DERM 2025 conference interview, Hebert highlights takeaways from her team’s findings on roflumilast cream in patients aged 3 months to 2 years with atopic dermatitis.

Post hoc analyses of the TENAYA and LUCERNE phase 3 trials indicated important endpoints that could signal the potential for treatment interval extension.

Hahn discusses his recent study evaluating AREDS’s potential for nonsubfoveal GA regression in response to a recent post hoc analysis.

Patient responses indicate that the device is simple and easy to use, and clinical data reflects its effectiveness in recognizing hallmark signals of AMD.

These data were presented at DERM 2025, highlighting recent findings on the impact of tralokinumab on atopic dermatitis.

Results from an extension study of the PHOTON trial indicate longer-lasting visual and anatomic improvements in patients receiving aflibercept 8mg versus 2mg.

A recent analysis of data from the phase 3 YOSEMITE/RHINE trials has indicated a greater reduction in hard exudates using faricimab versus aflibercept.

In a trial studying faricimab’s efficacy in Black, Hispanic/Latino, and Native American patients with DME, investigators found results consistent with the YOSEMITE/RHINE trials.

These pooled THRIVE-AA1 and THRIVE-AA2 study data highlight improvements in mental health among patients with alopecia given deuruxolitinib.

During this DERM 2025 interview segment, Martinez-Dulay touches on highlights from her sessions in which she explores allergic contact dermatitis.

This session was titled ‘The Hidden Undercurrent: When Hair Loss Isn’t Alopecia Areata’ and was presented at the DERM 2025 conference by April Armstrong, MD, MPH.

In her DERM 2025 conference interview, Martinez-Dulay highlights takeaways from her sessions on atopic dermatitis, prurigo nodularis, and lymphoma.

Cotter highlights his DERM 2025 conference presentation on navigating the diagnosis of melanoma and gene expression profiling of skin cancer.

This interview with Cotter highlights his session on the use of AI tools in the dermatology field.

This interview with Hure covers 2 of her sessions at DERM 2025, including a discussion of microplastics and forever chemicals, as well as the skin’s microbiome.

Swanson speaks in this interview segment about her DERM 2025 session on speaking with parents and their children or teens as a clinician.

This interim data was drawn from the TRACE study, highlighting real-world use of tralokinumab in adults with atopic dermatitis of the head and neck.

In this interview, Swanson highlights her DERM 2025 session ‘Systemic Therapy for the Pediatric Acne Patient’ and its takeaways.

In this DERM2025 interview, Friedman highlighted some of the discussion points from his presentation on off-label strategies for therapeutic challenges.

In this interview segment with Chilukuri, he highlights takeaways from his DERM 2025 session titled ‘Advancements in Body Contouring.’

In this discussion with Chilukuri, the most notable highlights from his DERM 2025 session ‘Skincare Secrets and Quick Fixes’ were covered.